Antah Pharma
Concise Prescribing Info
Endocrine, rheumatic & hematologic disorders; collagen, dermatologic, ophth, resp, neoplastic & GI diseases; acute exacerbation of multiple sclerosis, allergic & oedematous states; tuberculous meningitis w/ subarachnoid block.
Dosage/Direction for Use
Adult Adrenocortical insufficiency 4-12 mg daily as single or in divided doses, in conjunction w/ mineralocorticoid. Other indications 4-48 mg daily as single or in divided doses. Childn Adrenocortical insufficiency 117 mcg/kg or 3.3 mg/m2 daily as single or in divided doses, in conjunction w/ mineralocorticoid. Other indications 416 mcg-1.7 mg/kg or 12.5-50 mg/m2 daily as single or in divided doses.
Hypersensitivity. Systemic fungal infections.
Special Precautions
Hypothyroidism; ocular herpes simplex; psychotic derangement; nonspecific ulcerative colitis; active or latent TB, tuberculin reactivity; unusual stress. May mask signs of infection. Avoid rapid w/drawal. Prolonged use. May produce false -ve results to nitro blue tetrazolium test. Not to be used w/ live virus vaccines. Pregnancy & lactation. May suppress growth & development in childn.
Adverse Reactions
Fluid & electrolyte disturbance, CHF, hypokalaemic alkalosis, HTN. Muscle weakness, steroid myopathy, osteoporosis, vertebral compression fractures, femoral & humeral heads aseptic necrosis, pathologic fracture of long bones, tendon rupture. Peptic ulcer, small & large bowel perforation, pancreatitis, abdominal distention, ulcerative oesophagitis. Impaired wound healing, thin fragile skin, ecchymoses, erythema, increased sweating, allergic dermatitis, urticaria, angioneurotic oedema. Convulsions, increased intracranial pressure w/ papilloedema, vertigo, headache. Menstrual irregularities, development of cushingoid state. Suppression of growth in childn. Secondary adrenocortical & pituitary unresponsiveness. Decreased carbohydrate tolerance. DM manifestations. Increased insulin or oral hypoglycemic agent requirement in diabetic patients. Hirsutism, posterior subcapsular cataract. Increased IOP. Glaucoma, exophthalmos, hypersensitivity, thromboembolism, wt gain, increase appetite, nausea, malaise.
Drug Interactions
Enhanced metabolic clearance by phenytoin (diphenylhydantoin), phenobarb, ephedrine, rifampin. Altered response to coumarin anticoagulants. Development of hypokalemia w/ K-depleting diuretics. Increased systemic side effects w/ CYP3A inhibitors including cobicistat-containing products. Concomitant use w/ ASA in patients w/ hypoprothrombinemia.
MIMS Class
Corticosteroid Hormones
ATC Classification
H02AB08 - triamcinolone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.
A01AC01 - triamcinolone ; Belongs to the class of local corticosteroid preparations. Used in the treatment of diseases of the mouth.
Trinolone tab 4 mg
10 × 10's;100 × 10's;50 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in